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In the first year of this project, we have synthesized 
a number of new substrates for calpain I and II. The 
substrates were designed based on good transition-state 
inhibitors for calpain I. The following table gives 
representative hydrolysis data for a few of the substrates 
synthesized. The standard assay substrate for calpain I is 
Suc-Leu-Tyr-AMC (AMC = 4-methyl-7-aminocoumarin, a 
fluorescent leaving group). One of the substrates Ms-D-
Ser(Bzl)-Phe-AMC (Ms = methanesulfonyl, Ser(Bzl) = 0-
benzylserine) is a 2.8 fold better substrate that the 
standard substrate Suc-Leu-Tyr-AMC. 
Rate [AMC (M) ]/min * 1 0 1 0 
No. Substrate a Calpain I Calpain 
- Suc-Leu-Tyr-AMC 18.0 3.39 
4 Z-Leu-Abu-AMC 10.7 3.28 
5 Z-Leu-Leu-AMC 7.87 N.H. 
6 Z-Leu-Nle-AMC 10.3 2.97 
7 Z-Leu-Nva-AMC 15.3 5.65 
8 Z-Leu-Phe-AMC 4.73 6 . 01 
1 8 Ms--D-Ser(Bzl)-Phe-AMC 49.7 12.6 
1 9 Ac--D-Ser(Bzl)-Phe-AMC 3 .11 N.H. b 
a 4 1 JIM of substrate used in assay, which is the solubilit' 
limit of almost all substrates. bN.H. denotes no 
hydrolysis. 
We then measured K c a t / K M values with calpain I and II 
for the Suc-Leu-Tyr-AMC and Ms-D-Ser(Bzl)-Phe-AMC 
substrates. The values are shown in the following table. 
The new substrate Ms-D-Ser(Bzl)-Phe-AMC was 1.8 fold better 
than the standard assay substrate Suc-Leu-Tyr-AMC and has a 
selectivity factor for calpain I vs calpain II of 4.6 
compared to a value of 1.4 for Suc-Leu-Tyr-AMC. 
*cat/K m (M-is-l) 
Suc-Leu-Tyr-AMC Ms-D-Ser(Bzl)-Phe-AMC 
Calpain I Calpain II Calpain I Calpain II 
31.8 22.6 57.7 12.35 
Conclusion. We have prepared a new substrate for 
calpain I which is more reactive and more specific than the 
substrate in current use. 
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Background. The caspase and calpain families of cysteine proteases are 
involved in cell death and neurodegeneration following traumatic brain injury. Calpains, 
calcium activated cysteine proteases, have long been recognized as major players in the 
acute neurodegeneration that follows a stroke (Bartus et al. 1995). In addition, specific 
calpain inhibitors have been shown to reduce the neurodegeneration that follows a head 
injury in animal models (Saatman et al. 1996). The goal of our research is the design and 
synthesis of specific irreversible inhibitors for calpain for the treatment of peripheral 
axonal degeneration. 
Progress Report. The Powers laboratory has recently developed a novel series 
of specific inhibitors for cysteine proteases based on the epoxysuccinate moiety. These 
inhibitors irreversibly inhibit cysteine proteases through reaction of the epoxide of the 
inhibitor with the active site cysteine residue of the target cysteine protease. During this 
year, we have developed specific epoxide inhibitors of calpain. 
Epoxide inhibitors inhibit by forming a covalent bond with the cysteine residue in 
the protease active site (see the following figure). 
Once the enzyme is bound to the epoxide no reverse reaction is possible and the enzyme 
is irreversibly inactivated. The incorporation of an aza-peptide moiety into the inhibitor 
structure allows for increased hydrogen bonding with the enzyme. A representative 
structure of an aza-peptide epoxide is shown in the following figure. An aza-peptide 
residue is an amino acid with a nitrogen substituted for the a-carbon. To be specific, we 
will refer to ALeu when the a-carbon of the amino acid leucine is replaced with nitrogen 
The first structure (1) is a dipeptide aza-leucine derivative. The structure of a Leu-Phe 
dipeptide epoxysulfone (10) is also shown below. Epoxysulfones are derived from 
vinylsulfones, which are well known inhibitors of cysteine proteases. We will designate 
the epoxysulfone moiety as EPS. 
1 Z-Leu-ALeu-EP (S,S)-COOEt 10 Z-Leu-Phe-EPS-Ph 
Table 1 . Inhibition of Calpain I by Aza-peptides and Epoxysulfones.11 
No. Inhibitor 
Epoxides 
1 Z-Leu-ALeu-EP (S,S)-COOEt 8.58 
2 Z-Leu-ALeu-EP (R,R)-COOEt 6.70 
3 Z-Leu-ALeu-EP (cis)-COOEt NI 
4 Z-Leu-AHphe-EP (5,5)-COOEt 5.68 
5 Z-Leu-AHphe-EP (R,R)-COOEt 2.16 
6 Z-Leu-AHphe-EP (cis)-COOEt 1.03 
7 Z-Leu-AHphe-EP (S.^-COOH 2.12 
8 EtOOC-EP (S,S)-Leu-NH-(CH,)4-NH-Z 1,770 
9 HOOC-EP (S,S)-Leu-NH-(CH 2) 4-NH-Z 22,200 
Epoxysulfones 
10 Z-Leu-Phe-EPS-Ph 22.8 
11 Z-Val-Phe-EPS-Ph 2.96 
aALeu = aza-leucine, AHphe = aza-homophenylalanine, Z = carboxybenzoyl. 
Aza-peptide epoxides 1-7, with the peptide on the left side of the epoxide 
functional group, show weak potency as calpain inhibitors. All of these inhibitors have a 
P2 Leu residue, which is preferred by calpain. We also investigated the role of epoxide 
stereochemistry on inhibitor potency. Both the R,R and S,S isomers at the epoxide 
moiety were equally potent. We then investigated epoxides 8 and 9, which contain the 
peptide moiety on the right side of the epoxide functional group. These are more potent 
and indeed the most reactive derivative is 9. These inhibitors will be used as lead 
compounds for the development of more potent and specific calpain inhibitors in the 
coming year. Epoxysulfones 10-12 are a new class of calpain inhibitors, which also show 
modest inhibition. We expect that epoxysulfones inhibit calpain by a mechanism similar 
to the mechanism of epoxide inhibition (see first figure). We plan to improve the 
inhibitor potency of epoxysulfones as calpain inhibitors during the year. 
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Background. The caspase and calpain families of cysteine proteases are 
involved in cell death and neurodegeneration following traumatic brain injury. Calpains, 
calcium activated cysteine proteases, have long been recognized as major players in the 
acute neurodegeneration that follows a stroke (Bartus et al. 1995). In addition, specific 
calpain inhibitors have been shown to reduce the neurodegeneration that follows a head 
injury in animal models (Saatman et al. 1996). The goal of our research is the design and 
synthesis of specific irreversible inhibitors for calpain for the treatment of peripheral 
axonal degeneration. 
Progress Report. The Powers laboratory has recently developed a novel series 
of specific inhibitors for cysteine proteases based on the epoxysuccinate moiety. These 
inhibitors irreversibly inhibit cysteine proteases through reaction of the epoxide of the 
inhibitor with the active site cysteine residue of the target cysteine protease. Epoxide 
inhibitors inhibit by forming a covalent bond with the cysteine residue in the protease 
active site (see the following figure). During this year, we have developed specific 
epoxide inhibitors of calpain based on the structure of the natural inhibitor E-64c and 
incorporating aza-amino acids. 
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Once the enzyme is bound to the epoxide no reverse reaction is possible and the enzyme 
is irreversibly inactivated. The incorporation of an aza-peptide moiety into the inhibitor 
structure eliminates amino acid stereochemistry, changes the bond angles of amino acids, 
and provides new sites for possible hydrogen bonding to active sites. The structures of 
the natural epoxide E-64c and its aza-analog are shown in the following figure. An aza-
peptide residue is an amino acid with a nitrogen substituted for the a-carbon. To be 
specific, we will refer to ALeu when the a-carbon of the amino acid leucine is replaced 
with nitrogen. We will designate the epoxysulfone moiety as EPS. 
E64c (1) Aza E64c (2) 
Table 1. Inhibition of Calpain 1 by Aza-peptide epoxides." 
No. Inhibitor Us (M-V) 
Epoxides 
1 HO-EPS (S,S)-Leu-NH-(CH 2) 2-CH-(CH 3) 2 (E-64c) 17,200 
2 HO-EPS (S,S)-ALeu-NH-(CH 2) 2-CH-(CH 3) 2 1,370 
3 HO-EPS (S,S)-ALeu-NH-(CH 2) 4-NH-Z 1,450 
4 HO-EPS (S,S)-ALeu-NH-benzyl 1220 
5 HO-EPS (S,S)-ALeu-NH-(CH 2) 3-CH 3 840 
6 HO-EPS (S,S)-ALeu-0-(CH 2) 3-CH 3 1000 
7 HO-EPS (S,S)-ALeu-piperidine 1410 
aEPS = epoxysuccinate, ALeu = aza-leucine, Z = carboxybenzoyl. 
While the aza-peptide analogs of E64c are less potent than the parent compound, 
these inhibitors display significant inhibition of Calpain I. All of the best inhibitors 
contain the (S,S) epoxide stereochemistry and the carboxylic acid side chain. Epoxide 2 
is the direct comparison to E64c (1). Inhibitor 3, with a longer, aromatic side chain, 
shows a small improvement in potency. Epoxide 4, with a shorter chain aromatic, is not 
at potent as epoxide 3. In an attempt to increase the potency of epoxide 4, with an amino-
butyl side chain, the butyl ester analog 5 was synthesized. The ester allows for greater 
bond rotation, and does show an increase in potency. Epoxide 7 was also synthesized to 
improve bond rotation with the tri-substituted amine side chain, and displays an increase 
in potency. 
Another ongoing project is the synthesis of a fluorescently-labeled inhibitor for 
calpain to be used as a diagnostic tool for the presence of calpain. The structure of the 
inhibitor in synthesis can be seen in the following figure. This inhibitor will be used to 
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Background. The caspase and calpain families of cysteine proteases are involved 
in cell death and neurodegeneration following traumatic brain injury. Calpains, calcium 
activated cysteine proteases, have long been recognized as major players in the acute 
neurodegeneration that follows a stroke (Bartus et al. 1995). In addition, specific calpain 
inhibitors have been shown to reduce the neurodegeneration that follows a head injury in 
animal models (Saatman et al. 1996). The goal of our research is the design and 
synthesis of specific irreversible inhibitors for calpain for the treatment of peripheral 
axonal degeneration. 
Progress Report. The Powers laboratory has recently developed a series of 
specific inhibitors for cysteine proteases based on the epoxysuccinate moiety. These 
inhibitors irreversibly inhibit cysteine proteases through reaction of the epoxide of the 
inhibitor with the active site cysteine residue of the target cysteine protease. Epoxide 
inhibitors inhibit by forming a covalent bond with the cysteine residue in the protease 
active site (see the following figure). Once the enzyme is bound to the epoxide no 
reverse reaction is possible and the enzyme is irreversibly inactivated. 
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During this year, we have designed and synthesized a series of calpain inhibitors 
which are analogs of the epoxide inhibitor EP460. The structures of the natural epoxide 
E-64c and the most potent analog for calpain in the literature, EP460, are shown in the 
following figure. This year we have designed new analogs of EP460 substituting a 
variety of aromatics for the benzyl moiety in order to increase the potency and selectivity 





Table 1. Inhibition of Calpain I by peptide epoxides. 3 
No. Inhibitor k o b s (MV 1 ) 
1 HO-EPS (S,S)-Leu-NH-(CH 2 ) 2 -CH-(CH 3 )2 (E-64c) 7,200 
2 HO-EPS (S ,S) -Leu-NH-(CH 2 ) 4 -NH-Z (EP460) 15,200 
3 HO-EPS (S ,S) -Leu-NH-(CH 2 ) 4 -NH-CO-CH 2 -0 - l -naph thy l 21,600 
4 H O - E P S (S ,S) -Leu-NH-(CH 2 ) 4 -NH-CO-NH-l -naphthyl 20,000 
5 HO-EPS (S ,S)-Leu-NH-(CH 2 ) 4 -NH-CO-NH-benzyl 18,400 
6 HO-EPS (S,S)-Leu-NH-(CH 2 ) 4 -NH-CO-NH-2-phenoxyphenyl 15,600 
7 HO-EPS (S ,S)-Leu-NH-(CH 2 ) 4 -NH-CO-NH-phenyl 13,400 
a E P S = epoxysuccinate, Z = carbobenzyloxy. 
The most potent epoxide inhibitors for calpain from our study are shown in 
Table 1. EP460, the most potent epoxide inhibitor for calpain in the literature, is listed as 
inhibitor 2. We were able to create several inhibitors that are more potent than EP460. 
Inhibitors 3 and 4 are the most potent inhibitors and both contain a naphthyl moiety. The 
naphthyl ring probably binds in a large hydrophobic pocket in the calpain active site. The 
benzyl urea inhibitor 5 which has an O to NH substitution shows greater potency than 
EP460. The phenoxyphenyl derivative 6 also shows promising potency. Inhibitor 7, 
which is slightly less potent, demonstrates the importance of the methylene of the benzyl 
group for proper spacing in the calpain active site. Also, while these inhibitors showed 
increased potency for calpain, they showed decreasing potency for papain and cathepsin 
B compared to EP460. Therefore these inhibitors show increasing selectivity for calpain 
over papain and cathepsin B. Through this study, we have demonstrated that calpain 
accepts large aromatic groups near the S 3 subsite, and we have created the most potent 
epoxide inhibitor of calpain yet reported. 
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Background. The caspase and calpain families of cysteine proteases are involved 
in cell death and neurodegeneration following traumatic brain injury. Calpains, calcium 
activated cysteine proteases, have long been recognized as major players in the acute 
neurodegeneration that follows a stroke (Bartus et al. 1995). In addition, specific calpain 
inhibitors have been shown to reduce the neurodegeneration that follows a head injury in 
animal models (Saatman et al. 1996). The goal of our research is the design and 
synthesis of specific irreversible inhibitors for calpain for the treatment of peripheral 
axonal degeneration. 
Progress Report. The Powers laboratory has recently developed a series of 
specific inhibitors for cysteine proteases based on the epoxysuccinate moiety. These 
inhibitors irreversibly inhibit cysteine proteases through reaction of the epoxide of the 
inhibitor with the active site cysteine residue of the target cysteine protease. Epoxide 
inhibitors inhibit by forming a covalent bond with the cysteine residue in the protease 
active site (see the following figure). Once the enzyme is bound to the epoxide no 
reverse reaction is possible and the enzyme is irreversibly inactivated. 
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During this project, we have designed and synthesized a series of calpain 
inhibitors which are analogs of the epoxide inhibitor EP460 (2). The structures of the 
natural peptide epoxide E-64c (1) and the most potent inhibitor analog for calpain in the 
literature, EP460, are shown in the following figure. We have designed new analogs of 
EP460 by substituting a variety of aromatics for the benzyl moiety of EP460 in order to 
increase the potency and selectivity of the epoxide inhibitors for calpain and to gain 
information about the calpain active site. 
E64c(1) EP460 (2) 
Inhibition data for the new epoxides is shown in Table I. 
2 
Table 1. Inhibition of Calpain I by peptide epoxides.3 
% Inhibition of 
k o b s/[I] (MrV ') Calpain in 
Calpain I Calpain Cathepsin Papain PC12 Cells 
HO-EPS (S,S)-Leu-NH-C0 2-benzyl (EP460) 15,200 78,300 834,000 95 
23a EtO-EPS (S,S)-Leu-NH-C0 2-benzyl 500 1,520 120 510 90 
24b HO-EPS (S,S)-Leu-NH-CONH-benzyl 18,400 40,700 32,400 203,000 42 
24c HO-EPS (S,S)-Leu-NH-CONH-phenyl 13,400 41,200 36,000 308,000 ND 
24d HO-EPS (S,S)-Leu-NII-CONH-(4-methoxyphenyl) 11,500 28,300 30,000 387,000 73 
24e HO-EPS (S,S)-Leu-NH-COCH2-(3-pyridyl) 3,080 8,060 19,500 188,000 ND 
24f HO-EPS (S,S)-Leu-NH-COCH 20-(l-naphthyl) 21,600 46,500 42,500 232,000 81 
24g HO-EPS (S,S)-Leu-NH-COCH20-(2-naphthyl) 12,400 20,200 17,600 194,000 ND 
24h HO-EPS (S,S)-Leu-NH-CONH-(l -naphthyl) 20,000 44,000 45,100 666,000 70 
24i HO-EPS (S,S)-Leu-NH-CONH-(2-phenoxyphenyl) 15,600 39,500 57,300 651,000 84 
ND = not determined; EPS = epoxysuccinate. 
3 
All of the inhibitors in Table 1 are irreversible inhibitors with second order 
inhibition rate constants (k o b s/[I]) with calpains as high as 46,000 NT's 1 . Many of the 
inhibitors synthesized were more potent with calpain I and II than EP460. The best 
inhibitors for the calpains incorporated the 1-naphthyl moiety (24f, 24h). The benzyl 
urea compound (24b) and the phenoxyphenyl urea (24i) were also potent inhibitors. The 
EP460 analog containing an ethyl ester (23a) on the epoxysuccinate moiety was a 
significantly less potent inhibitor with all of the enzymes, demonstrating the importance 
of the terminal epoxide carboxylic acid for inhibitor binding. Generally, the best 
inhibitors for calpain I and calpain II had the same structure, however the inhibitor 
potency with calpain II was 2-fold greater than calpain I. It is worth noting that while 
some of the inhibitors demonstrated greater inhibitory potency with calpain than EP460, 
all of the new inhibitors are significantly less potent than EP460 with cathepsin B and 
papain. A few of the inhibitors (24b, 24c, 24f) are even more potent with calpain II than 
with cathepsin B. Thus, the design changes had increased the specificity of the inhibitors 
for calpain vs cathepsin B. The inhibitors also inhibited the cysteine protease papain with 
high rate constants. Since papain is not a human protease, selectivity over papain is 
inconsequential for our purposes of drug development. In summary, we have succeeded 
in the discovery of new epoxide calpain inhibitors that are more potent and selective than 
EP460. 
The best of these inhibitors were also tested in cells for their ability to inhibit 
calpain activity in PC 12 cells, a breast cancer cell line, induced by the chemotherapy drug 
taxol by Dr. Jonathan Glass at Emory University. One of the side effects of the drug 
taxol in humans is peripheral neuropathy, where patients experience tingling and loss of 
sensation in the limbs. Dr. Glass has demonstrated that the addition of taxol to PC 12 
cells spikes the calpain proteolytic activity present in the cells. These results indicate that 
calpain is involved in the mechanism by which taxol induces peripheral neuropathy. One 
of the many therapeutic possibilities of calpain inhibitors such as these epoxides is to 
treat this side effect of taxol. 
The results of this cell study can be seen in Table 1. The results are reported as % 
inhibition of calpain relative to the amount of spiked calpain activity with taxol alone. 
Several of the epoxide inhibitors proved to be more potent calpain inhibitors than the ct-
ketoamide AK295, a hallmark calpain inhibitor, in this assay. EP460 (24a) is the most 
potent inhibitor in this assay, along with the ethyl ester derivative 23a. Although the 23a 
is a much weaker inhibitor in vitro studies, the ethyl ester is hydrolyzed by esterases in 
cells, generating the more potent acid form 24a. It is therefore reasonable that 23a and 
24a have differing potencies in vitro, but inhibit similarly in cells. The methoxyphenyl 
and phenoxyphenyl inhibitors 24d and 24i were the most potent of the new inhibitors in 
this assay. It is interesting to note that 24d and 24i were not the most potent in vitro. It 
seems that these inhibitors are more bioavailable and better able to cross the cell 
membrane to reach the calpain. This experiment demonstrates that these epoxide 
inhibitors are able to cross cell membranes and efficiently inhibit calpain in a cell culture, 
which is an important step toward their development as therapeutic agents. 
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